Denintuzumab
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A) . Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia[1].
Product Specifications
CAS Number
[1630074-14-4]
Product Name Alternative
HBU 12
UNSPSC
12352203
Target
ADC Antibody; CD19
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/denintuzumab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Denintuzumab]
Molecular Weight
(145.96 kDa)
References & Citations
[1]Farhadfar N, et al. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016 Oct;49:13-21.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Goat Polyclonal Beta-13-N-Acetylglucosaminyltransferase 2/B3GNT2 Antibody
